NEW YORK ─ Bio-Me said Wednesday it has received €2 million ($2.2 million) in grants and public funding from the Norwegian Research Council to develop a companion diagnostic test for immune checkpoint inhibitor cancer treatments.
Its development involves key Norwegian and international partners and a collaboration between leading clinical experts and academic researchers in the field, Bio-Me said.